Genprex Inc. (NASDAQ:GNPX) Stock Continues to Consolidate: How to Trade Now?
Genprex Inc. (NASDAQ:GNPX) is moving in range after the company announced that its CEO and president Rodney Varner would participate in the webinar series with CEO Roadshow to offer the company’s views to investors each month from July to September 2021.
In addition, the CEO will be available to answer questions after every presentation. The CEO Roadshow is a webinar series featuring small-cap and mid-cap stocks that are almost breaking out or having near-term developments that make them attractive in their long-term investment opportunities.
Recently, Genprex announced that the FDA had evaluated and confirmed all comments regarding its clinical study protocol for the Acclaim-1 clinical study. The acclaim-1 study is a multi-center, open-label phase 1/2 clinical study assessing REQORSA Immunogene Therapy combined with AstraZeneca’s Tagrisso in patients suffering from late-stage non-small cell lung cancer whose diseases has progressed following Tagrisso treatment. The FDA granted Genptrex Fast Track Designation in January 2020 for the Acclaim-1 patient population. So in the coming months, GNPX is a stock to watch.
Market Reaction:
On Tuesday, GNPX stock jumped 4% at $3.09 with more than 470k shares, compared to its average volume of 655k shares. The stock has moved within a range of $3.0000 – 3.1600 after opening the trade at $3. Over the past 52-week, the stock has been trading within a range of $2.8000 – 7.7200.
